Correction to: Trials
https://doi.org/10.1186/s13063-019-3409-1
Following publication of the original article [1], we have been notified that the end note would need to be adjusted.
Originally published note:
-
During the revision process of this paper, it became apparent that the study product iHIVARNA-01 contains an error in that the RNA sequence contained by mistake a second start codon in front of the HTI immunogen coding sequence. This error is likely to influence the expression of the HTI protein, from the mRNA vaccine. Even though the degree to which this impacted the expression of HTI remains unclear, the results of the preclinical trial show that there is sufficient expression for the induction of an immunogen-specific T-cell response in mice.
Corrected end note:
-
After completing the phase I and phase II trial, it became apparent that the study product iHIVARNA-01 contains an error in that the RNA sequence contained by mistake a second start codon upstream of the HTI immunogen coding sequence. This error is likely to influence the expression of the HTI protein, from the mRNA vaccine. The degree to which this impacted the expression of HTI remains unclear. The results of the preclinical study showed an induction of an immunogen specific T cell response in mice which could not be correlated with known HTI expression as the expression level of the HTI peptide has not been assessed. Similarly, in the clinical studies, the level of expression of the immunogen was not quantified.
Reference
Jong, et al. iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. Trials. 2019;20:361. https://doi.org/10.1186/s13063-019-3409-1.
Author information
Authors and Affiliations
Consortia
Corresponding authors
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
de Jong, W., Aerts, J., Allard, S. et al. Correction to: iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. Trials 20, 721 (2019). https://doi.org/10.1186/s13063-019-3940-0
Published:
DOI: https://doi.org/10.1186/s13063-019-3940-0